文献速递MDS 与骨髓增殖性肿瘤血栓与止血

原发性血小板增多症:2024年诊断、风险分层和管理更新

Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
PubMed 文献 · Am J Hematol · 2024-01-25

本文综述原发性血小板增多症的诊断标准、遗传学特征、生存预后、血栓风险分层及治疗策略。诊断需血小板≥450×10^9/L并排除其他髓系肿瘤,约80%患者携带JAK2、CALR或MPL驱动突变。治疗主要目标是预防血栓,所有患者建议每日低剂量阿司匹林,高危患者建议降细胞治疗。

要点

  • 诊断需血小板≥450×10^9/L并排除其他髓系肿瘤,骨髓形态示成熟巨核细胞增多呈松散簇分布。
  • 约80%患者携带JAK2、CALR或MPL驱动突变且互斥,约50%携带其他突变如TET2、ASXL1。
  • 治疗目标为预防血栓,所有患者建议每日低剂量阿司匹林,高危患者建议降细胞治疗。

核心结论

  • 原发性血小板增多症是一种JAK2突变高发的骨髓增殖性肿瘤,临床病程常惰性但可能被血栓或出血并发症打断。
  • 治疗主要目标是预防血栓,低剂量阿司匹林建议用于所有患者,降细胞治疗建议用于高危患者。

研究设计与样本

  • 本文为综述,纳入原发性血小板增多症诊断、风险分层和管理更新内容,未报告检索范围。

主要发现

  • 约80%患者表达JAK2、CALR或MPL驱动突变且互斥,约50%携带其他突变,最常见为TET2(9%-11%)、ASXL1(7%-20%)、DNMT3A(7%)和SF3B1(5%)。
  • 异常核型见于<10%患者,包括+9/20q-/13q-。
  • 中位生存期约18年,年轻患者超过35年;三重A生存风险模型基于年龄、中性粒细胞绝对计数和淋巴细胞绝对计数,将患者分为高危、中危-1、中危-2和低危,对应中位生存期分别为8、14、21和47年。
  • 10年白血病转化率<1%,但JAK2突变伴极度血小板增多和异常核型患者可能更高。
  • MPL和CALR-1突变与骨髓纤维化转化风险增加相关,剪接体突变与较差总生存和无骨髓纤维化生存相关,TP53与白血病转化相关,JAK2V617F与血栓形成相关。

关键数值与推荐

  • 诊断需血小板≥450×10^9/L,并排除其他髓系肿瘤包括前纤维化骨髓纤维化、真性红细胞增多症、慢性髓性白血病和伴环形铁粒幼细胞和血小板增多的骨髓增生异常综合征。
  • 血栓风险分四类:极低危(年龄≤60岁、无血栓史、JAK2野生型)、低危(同极低危但JAK2突变阳性)、中危(同低危但年龄>60岁)、高危(有血栓史或年龄>60岁伴JAK2突变)。
  • 所有患者建议每日一次低剂量阿司匹林,低危患者建议每日两次。
  • 高危患者建议降细胞治疗,中危患者可选。
  • 一线降细胞药物为羟基脲和聚乙二醇干扰素-α,二线为白消安。

临床怎么用

  • 所有患者建议每日一次低剂量阿司匹林,低危患者建议每日两次。
  • 高危患者建议降细胞治疗,中危患者可选降细胞治疗。
  • 一线降细胞药物选择羟基脲和聚乙二醇干扰素-α,二线为白消安。
  • 综述还包括极度血小板增多、妊娠、内脏静脉血栓、围手术期管理和原发性血小板增多症后骨髓纤维化的特定治疗策略及新研究药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microcirculatory symptoms (e.g., headaches, lightheadedness, and acral paresthesias), and, less frequently, by disease transformation into myelofibrosis (MF) or acute myeloid leukemia. DIAGNOSIS: In addition to thrombocytosis (platelets ≥450 × 109 /L), formal diagnosis requires the exclusion of other myeloid neoplasms, including prefibrotic MF, polycythemia vera, chronic myeloid leukemia, and myelodysplastic syndromes with ring sideroblasts and thrombocytosis. Bone marrow morphology typically shows increased number of mature-appearing megakaryocytes distributed in loose clusters. GENETICS: Approximately 80% of patients express myeloproliferative neoplasm driver mutations (JAK2, CALR, MPL), in a mutually exclusive manner; in addition, about 50% harbor other mutations, the most frequent being TET2 (9%-11%), ASXL1 (7%-20%), DNMT3A (7%), and SF3B1 (5%). Abnormal karyotype is seen in <10% of patients and includes +9/20q-/13q-. SURVIVAL AND PROGNOSIS: Life expectancy is less than that of the control population. Median survival is approximately 18 years but exceeds >35 years in younger patients. The triple A survival risk model, based on Age, Absolute neutrophil count, and Absolute lymphocyte count, effectively delineates high-, intermediate-1-, intermediate-2-, and low-risk disease with corresponding median survivals of 8, 14, 21, and 47 years. RISK FACTORS FOR THROMBOSIS: Four risk categories are considered: very low (age ≤60 years, no thrombosis history, JAK2 wild-type), low (same as very low but JAK2 mutation present), intermediate (same as low but age >60 years), and high (thrombosis history or age >60 years with JAK2 mutation). MUTATIONS AND PROGNOSIS: MPL and CALR-1 mutations have been associated with increased risk of MF transformation; spliceosome with inferior overall and MF-free survival; TP53 with leukemic transformation, and JAK2V617F with thrombosis. Leukemic transformation rate at 10 years is <1% but might be higher in JAK2-mutated patients with extreme thrombocytosis and those with abnormal karyotype. TREATMENT: The main goal of therapy is to prevent thrombosis. In this regard, once-daily low-dose aspirin is advised for all patients and twice daily for low-risk disease. Cytoreductive therapy is advised for high-risk and optional for intermediate-risk disease. First-line cytoreductive drugs of choice are hydroxyurea and pegylated interferon-α and second-line busulfan. ADDITIONAL CONTENT: The current review includes specific treatment strategies in the context of extreme thrombocytosis, pregnancy, splanchnic vein thrombosis, perioperative care, and post-essential thrombocythemia MF, as well as new investigational drugs.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Vannucchi AM, Barbui T, et al. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024. PMID: 38269572. doi:10.1002/ajh.27216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。